*Refresh the page if the below document does not appear.
Zydus has received final approval from the regulatory body to market Capriprazine Capsules USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg dose capsules and indicated as an atypical antipsychotic and also for acute treatment of maniac or mixed episodes of bipolar disorder.
67221 shares of Astrazeneca Pharma India Ltd were traded on the NSE, an increase of 11.45 times the two-week daily average volume of 5870 shares. The share price increased by 6.50% to Rs.3,300.00.
DFE Pharma, a provider of pharmaceutical and nutraceutical excipient solutions launched its Centre of Excellence designated as C2F i.e Closer to the formulator. The company deals with pre registration work, including development, scale up and so on, particularly related to OSD’s.
A team of researchers from Tata Memorial Centre, Mumbai has shown that a local Anesthesia drug lignocaine has been found to improve the cure rates and increased survival rates in patients suffering from breast cancer.
The company fell 1.61% to ₹ 1372.60 after the US regulatory body inspected it’s Dahej manufacturing unit and issued it Form 483 with two procedural observations.
Although Lumakras showed no significant difference in overall survival compared to one other treatment, the pill did reduce the risk of disease progression in patients with advance lung cancer by 34%.
The company announced the grant of
permission to conduct a phase 1 clinical
study of an intravenous formulation of DMT
indicated for the treatment of stroke.